Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon ?-Reference-Cited by-同舟云学术

Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon ?

Published:2021-07-26 Issue:4 Volume:195 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Fattizzo Bruno¹²^ORCID,Rizzo Lorenzo³^ORCID,Giannotta Juri Alessandro¹^ORCID,Mazzon Federico³,Cecchi Nicola²,Frangi Claudia³,Barcellini Wilma¹^ORCID,Riva Marta³

Affiliation:

1. Hematology Unit Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

2. Department of Oncology and Oncohematology University of Milan Milan Italy

3. Department of Hematology and Oncology Niguarda Cancer Center ASST Ospedale Niguarda Milan Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17722

Reference10 articles.

1. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

2. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

3. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

4. Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epoetin alfa biosimilar (HX575): A review of 15 years’ post-approval clinical experience;Critical Reviews in Oncology/Hematology;2023-01

2. Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes;Cancers;2022-10-09

3. Erythropoiesis stimulants;Reactions Weekly;2022-08-13